These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 32770353)
1. Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Shi R; Lu T; Ku G; Ding H; Saito T; Gibiansky L; Agarwal P; Li X; Jin JY; Girish S; Miles D; Li C; Lu D Cancer Chemother Pharmacol; 2020 Sep; 86(3):347-359. PubMed ID: 32770353 [TBL] [Abstract][Full Text] [Related]
2. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma. Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808 [TBL] [Abstract][Full Text] [Related]
4. Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma. Lu T; Gibiansky L; Li X; Li C; Shi R; Agarwal P; Hirata J; Miles D; Chanu P; Girish S; Jin JY; Lu D Leuk Lymphoma; 2020 Dec; 61(12):2905-2914. PubMed ID: 32705923 [TBL] [Abstract][Full Text] [Related]
5. Ethnic sensitivity assessment: Polatuzumab vedotin pharmacokinetics in Asian and non-Asian patients with previously untreated diffuse large B-cell lymphoma in POLARIX. Liao MZ; Deng R; Gibiansky L; Lu T; Agarwal P; Dere R; Lee C; Hirata J; Herbaux C; Salles G; Li C; Miles D Clin Transl Sci; 2023 Dec; 16(12):2744-2755. PubMed ID: 37864313 [TBL] [Abstract][Full Text] [Related]
6. Safety and pharmacokinetics of polatuzumab vedotin in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma: a phase 1 dose-escalation study. Kinoshita T; Hatake K; Yamamoto K; Higuchi Y; Murakami S; Terui Y; Yokoyama M; Maruyama D; Makita S; Hida Y; Saito T; Tobinai K Jpn J Clin Oncol; 2021 Jan; 51(1):70-77. PubMed ID: 33029633 [TBL] [Abstract][Full Text] [Related]
7. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442 [TBL] [Abstract][Full Text] [Related]
8. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Abrisqueta P; González-Barca E; Panizo C; Pérez JMA; Miall F; Bastos-Oreiro M; Triguero A; Banerjee L; McMillan A; Seymour E; Hirata J; de Guzman J; Sharma S; Jin HY; Musick L; Diefenbach C Lancet Haematol; 2024 Feb; 11(2):e136-e146. PubMed ID: 38190832 [TBL] [Abstract][Full Text] [Related]
9. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma. Walji M; Assouline S Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586 [TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and exposure-response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study. Deng R; Gibiansky L; Lu T; Flowers CR; Sehn LH; Liu Q; Agarwal P; Liao MZ; Dere R; Lee C; Man G; Hirata J; Li C; Miles D CPT Pharmacometrics Syst Pharmacol; 2024 Jun; 13(6):1055-1066. PubMed ID: 38622879 [TBL] [Abstract][Full Text] [Related]
11. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma. Bourbon E; Salles G Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972 [TBL] [Abstract][Full Text] [Related]
12. Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma. Lu D; Lu T; Gibiansky L; Li X; Li C; Agarwal P; Shemesh CS; Shi R; Dere RC; Hirata J; Miles D; Chanu P; Girish S; Jin JY CPT Pharmacometrics Syst Pharmacol; 2020 Jan; 9(1):48-59. PubMed ID: 31749251 [TBL] [Abstract][Full Text] [Related]
13. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412 [TBL] [Abstract][Full Text] [Related]
14. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429 [TBL] [Abstract][Full Text] [Related]